Genomics

Kala Bio's new deal with Virotek isn't just about eye care. It's a capital-efficient pivot that tests its new identity and bets on a commercial present.

By appointing two legendary specialists, XGEN isn't just shuffling its board. It's aiming to legitimize whole genome sequencing for all IVF patients.

A $10M federal contract aims to slash the 7-year wait for rare disease diagnoses. Discover how Probably Genetic's AI and direct-to-patient data are leading the charge.

A landmark UCSF study has mapped the molecular machinery of autism, revealing convergent pathways. This isn't just a breakthrough for ASD; it's a new model for drug discovery.

A landmark study reveals that children of centenarians inherit a powerful biological advantage, rewriting our understanding of aging, health, and longevity.

A new partnership merges genetic screening and sperm analysis, promising empowered family planning. But as data deepens, are we crossing an ethical frontier?

A shocking $90M guidance cut and a securities probe at Myriad Genetics reveal more than a bad quarter; they expose deep cracks in the genetic testing market.

Colossal Foundation's rewilding fund offers cash and genetic tech to save seven species. But can a $250k budget tackle a $5M problem and prove its model?

A reported net loss obscures core growth at 10x Genomics. An acquisition, key partnerships, and a blockbuster product launch signal a decisive strategic pivot.

With a new $345 genome and major clinical wins, PacBio pushes boundaries. But can its strategic restructuring and bold R&D overcome mounting financial losses?

Strong Q2 results, pivotal deals with AstraZeneca and MSK, and a clear path to profitability signal SOPHiA GENETICS is converting its AI platform into market leadership.

MGI Tech's strategic alliance with NCSTAR in Queensland is set to accelerate medical breakthroughs by providing a full suite of cutting-edge 'multi-omics' tools.

Human Longevity's new low-cost whole genome sequencing promises predictive health for all, but its true power lies in its AI and a vast new data asset.

With $100M in total funding, bioinformatics firm Inocras plans to challenge U.S. precision oncology leaders by leveraging its whole-genome sequencing success in Asia.

BGLC aims to upend cancer monitoring in emerging markets with a low-cost liquid biopsy. But can a micro-cap execute on this billion-dollar vision?

A 49% stock plunge and a major acquisition write-down have thrust GeneDx into legal turmoil. We deconstruct the securities fraud claims and what they reveal.

Labcorp's new direct-to-consumer genetic panel promises early risk detection. But does it create a new set of challenges for patients and doctors?

After a disastrous Q2 report and lowered guidance, all eyes are on Azenta's August 5th call. We dissect the key metrics and strategic shifts to watch.

City of Hope's new trial, funded by ARPA-H, uses DNA mapping to predict immunotherapy success, promising a new era of personalized care for lung cancer.